Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate CancerAlberto Martini, Alberto Briganti, Giorgio Gandaglia et al.|European Urology Oncology|2019Cited by 86
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysisGiuseppe Fallara, Alberto Martini, Laura Marandino et al.|Cancer Treatment Reviews|2022Cited by 33
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysisGiuseppe Fallara, Alberto Martini, Federico Belladelli et al.|Critical Reviews in Oncology/Hematology|2022Cited by 13
Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate CancerGiuseppe Fallara, Alberto Martini, Daniele Robesti et al.|European Urology Open Science|2023Cited by 8
The immune‐related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trialsDaniele Robesti, Alberto Martini, Luigi Nocera et al.|British Journal of Urology|2023Cited by 8